Recombinant poxvirus expressing homologous genes inserted into the poxviral genome

Abstract

The present invention relates to a recombinant poxvirus vector capable of expressing two or more homologous, foreign sequences, which derive from different variants of a microorganism, and which have a homology of 50% or above. The invention further relates to a method for preparing such recombinant poxvirus and the use of such recombinant poxvirus as medicament or vaccine. Additionally, a method for affecting preferably inducing, an immune response in a living animal, including a human, is provided.

1 - 27 . (canceled) 
     
     
         28 . A recombinant MVA expressing at least two exogenous sequences,
 wherein the expression of each of the exogenous sequences is controlled by the same poxyiral transcriptional control element.   
     
     
         29 . The recombinant MVA of  claim 28 , wherein each of the transcriptional control elements is a vaccinia virus promoter. 
     
     
         30 . The recombinant MVA of  claim 29 , wherein each of the transcriptional control elements is a vaccinia virus p7.5 promoter. 
     
     
         31 . The recombinant MVA of  claim 28 , wherein each of the exogenous sequences is inserted at a naturally occurring deletion site of the MVA genome. 
     
     
         32 . The recombinant MVA of  claim 29 , wherein each of the exogenous sequences is inserted at a naturally occurring deletion site of the MVA genome. 
     
     
         33 . The recombinant MVA of  claim 30 , wherein each of the exogenous sequences is inserted at a naturally occurring deletion site of the MVA genome. 
     
     
         34 . The recombinant MVA of  claim 28 , wherein each of the exogenous sequences is inserted at an intergenic region of the MVA genome. 
     
     
         35 . The recombinant MVA of  claim 29 , wherein each of the exogenous sequences is inserted at an intergenic region of the MVA genome. 
     
     
         36 . The recombinant MVA of  claim 30 , wherein each of the exogenous sequences is inserted at an intergenic region of the MVA genome. 
     
     
         37 . The recombinant MVA of  claim 28 , wherein two exogenous sequences are inserted into the MVA genome at different insertion sites. 
     
     
         38 . The recombinant MVA of  claim 29 , wherein two exogenous sequences are inserted into the MVA genome at different insertion sites. 
     
     
         39 . The recombinant MVA of  claim 30 , wherein two exogenous sequences are inserted into the MVA genome at different insertion sites. 
     
     
         40 . The recombinant MVA of  claim 28 , wherein three exogenous sequences are inserted into the MVA genome at different insertion sites. 
     
     
         41 . The recombinant MVA of  claim 29 , wherein three exogenous sequences are inserted into the MVA genome at different insertion sites. 
     
     
         42 . The recombinant MVA of  claim 30 , wherein three exogenous sequences are inserted into the MVA genome at different insertion sites. 
     
     
         43 . The recombinant MVA of  claim 28 , wherein the exogenous sequences encode Dengue virus antigens. 
     
     
         44 . The recombinant MVA of  claim 29 , wherein the exogenous sequences encode Dengue virus antigens. 
     
     
         45 . The recombinant MVA of  claim 30 , wherein the exogenous sequences encode Dengue virus antigens. 
     
     
         46 . The recombinant MVA of  claim 40 , wherein the exogenous sequences are inserted into IGR 136-137, IGR 07-08, and IGR 44-45 of the MVA genome. 
     
     
         47 . The recombinant MVA of  claim 41 , wherein the exogenous sequences are inserted into IGR 136-137, IGR 07-08, and IGR 44-45 of the MVA genome. 
     
     
         48 . The recombinant MVA of  claim 42 , wherein the exogenous sequences are inserted into IGR 136-137, IGR 07-08, and IGR 44-45 of the MVA genome.